Indeed, FAK activation associated with α5 upregulation in response to c-Met inhibitor cabozantinib appears to reduce its anti-tumour effects, whereas combination of cabozantinib with FAK inhibitor CT-707 improves therapeutic activity as shown through increased apoptosis in vitro and reduced tumour growth in HCC xenografts (Wang et al., 2016). Here, MET is linked to neoplasm.